Publication

Immune microenvironment composition in non-small cell lung cancer and its association with survival

Tamminga, M., Hiltermann, T. J. N., Schuuring, E., Timens, W., Fehrmann, R. S. N. & Groen, H. J. M., 12-Jun-2020, In : Clinical & translational immunology. 9, 6, 13 p., 1142.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Tamminga, M., Hiltermann, T. J. N., Schuuring, E., Timens, W., Fehrmann, R. S. N., & Groen, H. J. M. (2020). Immune microenvironment composition in non-small cell lung cancer and its association with survival. Clinical & translational immunology, 9(6), [1142]. https://doi.org/10.1002/cti2.1142

Author

Tamminga, Menno ; Hiltermann, Thijo Jeroen N. ; Schuuring, Ed ; Timens, Wim ; Fehrmann, Rudolf S. N. ; Groen, Harry J. M. / Immune microenvironment composition in non-small cell lung cancer and its association with survival. In: Clinical & translational immunology. 2020 ; Vol. 9, No. 6.

Harvard

Tamminga, M, Hiltermann, TJN, Schuuring, E, Timens, W, Fehrmann, RSN & Groen, HJM 2020, 'Immune microenvironment composition in non-small cell lung cancer and its association with survival', Clinical & translational immunology, vol. 9, no. 6, 1142. https://doi.org/10.1002/cti2.1142

Standard

Immune microenvironment composition in non-small cell lung cancer and its association with survival. / Tamminga, Menno; Hiltermann, Thijo Jeroen N.; Schuuring, Ed; Timens, Wim; Fehrmann, Rudolf S. N.; Groen, Harry J. M.

In: Clinical & translational immunology, Vol. 9, No. 6, 1142, 12.06.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Tamminga M, Hiltermann TJN, Schuuring E, Timens W, Fehrmann RSN, Groen HJM. Immune microenvironment composition in non-small cell lung cancer and its association with survival. Clinical & translational immunology. 2020 Jun 12;9(6). 1142. https://doi.org/10.1002/cti2.1142


BibTeX

@article{36f903fe0e4441ec87d7a729e858cb69,
title = "Immune microenvironment composition in non-small cell lung cancer and its association with survival",
abstract = "Objectives In non-small cell lung cancer (NSCLC), the immune system and possibly its composition affect survival. In thisin silicostudy, the immune infiltrate composition in NSCLC patients was evaluated. Methods Gene expression data of tumors from early NSCLC patients were obtained from Gene Expression Omnibus (GEO). With CIBERSORT, 22 immune cell fractions were estimated. Results The immune infiltrate of 1430 pretreatment NSCLC patients contained mostly plasma cells, macrophages and CD8 T cells. Higher fractions of resting mast and CD4 T-helper cells were associated with longer overall survival (OS) (HR = 0.95,P <0.01; HR = 0.98, = 0.04, respectively) and higher fractions of M2 macrophages and active dendritic cells with shorter survival (HR = 1.02,P = 0.03; HR = 1.03,P = 0.05, respectively). Adenocarcinoma patients with survival data (n = 587) showed higher fractions of resting mast and resting CD4 T cells, and lower M0 macrophages than squamous cell carcinoma (n = 254), which were associated with OS (HR = 0.95,P = 0.04; HR = 0.97,P = 0.01; HR = 1.03,P = 0.01, respectively). Fractions of memory B cells, naive CD4 T cells and neutrophils had different associations with survival depending on the subtype. Smokers had had higher fractions of regulatory T cell, follicular helper T cell, neutrophil and M2 macrophage, which were associated with shorter survival (HR = 1.3,P <0.01; HR = 1.13,P = 0.02; HR = 1.09,P = 0.03; HR = 1.04,P = 0.02, respectively). Conclusion Pretreatment differences in immune cell composition in NSCLC are associated with survival and depend on smoking status and histological subtype. Smokers' immune composition is associated with lower survival.",
keywords = "adenocarcinoma, biostatistics, immune microenvironment, non-small cell lung cancer, smoking, squamous cell carcinoma, TUMOR-INFILTRATING LYMPHOCYTES, MAST-CELLS, T-CELLS, PROGNOSTIC BIOMARKER, CIGARETTE-SMOKING, EXPRESSION, LANDSCAPE, MACROPHAGES, BLOCKADE, PD-L1",
author = "Menno Tamminga and Hiltermann, {Thijo Jeroen N.} and Ed Schuuring and Wim Timens and Fehrmann, {Rudolf S. N.} and Groen, {Harry J. M.}",
note = "{\circledC} 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.",
year = "2020",
month = "6",
day = "12",
doi = "10.1002/cti2.1142",
language = "English",
volume = "9",
journal = "Clinical & translational immunology",
issn = "2050-0068",
publisher = "Wiley",
number = "6",

}

RIS

TY - JOUR

T1 - Immune microenvironment composition in non-small cell lung cancer and its association with survival

AU - Tamminga, Menno

AU - Hiltermann, Thijo Jeroen N.

AU - Schuuring, Ed

AU - Timens, Wim

AU - Fehrmann, Rudolf S. N.

AU - Groen, Harry J. M.

N1 - © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.

PY - 2020/6/12

Y1 - 2020/6/12

N2 - Objectives In non-small cell lung cancer (NSCLC), the immune system and possibly its composition affect survival. In thisin silicostudy, the immune infiltrate composition in NSCLC patients was evaluated. Methods Gene expression data of tumors from early NSCLC patients were obtained from Gene Expression Omnibus (GEO). With CIBERSORT, 22 immune cell fractions were estimated. Results The immune infiltrate of 1430 pretreatment NSCLC patients contained mostly plasma cells, macrophages and CD8 T cells. Higher fractions of resting mast and CD4 T-helper cells were associated with longer overall survival (OS) (HR = 0.95,P <0.01; HR = 0.98, = 0.04, respectively) and higher fractions of M2 macrophages and active dendritic cells with shorter survival (HR = 1.02,P = 0.03; HR = 1.03,P = 0.05, respectively). Adenocarcinoma patients with survival data (n = 587) showed higher fractions of resting mast and resting CD4 T cells, and lower M0 macrophages than squamous cell carcinoma (n = 254), which were associated with OS (HR = 0.95,P = 0.04; HR = 0.97,P = 0.01; HR = 1.03,P = 0.01, respectively). Fractions of memory B cells, naive CD4 T cells and neutrophils had different associations with survival depending on the subtype. Smokers had had higher fractions of regulatory T cell, follicular helper T cell, neutrophil and M2 macrophage, which were associated with shorter survival (HR = 1.3,P <0.01; HR = 1.13,P = 0.02; HR = 1.09,P = 0.03; HR = 1.04,P = 0.02, respectively). Conclusion Pretreatment differences in immune cell composition in NSCLC are associated with survival and depend on smoking status and histological subtype. Smokers' immune composition is associated with lower survival.

AB - Objectives In non-small cell lung cancer (NSCLC), the immune system and possibly its composition affect survival. In thisin silicostudy, the immune infiltrate composition in NSCLC patients was evaluated. Methods Gene expression data of tumors from early NSCLC patients were obtained from Gene Expression Omnibus (GEO). With CIBERSORT, 22 immune cell fractions were estimated. Results The immune infiltrate of 1430 pretreatment NSCLC patients contained mostly plasma cells, macrophages and CD8 T cells. Higher fractions of resting mast and CD4 T-helper cells were associated with longer overall survival (OS) (HR = 0.95,P <0.01; HR = 0.98, = 0.04, respectively) and higher fractions of M2 macrophages and active dendritic cells with shorter survival (HR = 1.02,P = 0.03; HR = 1.03,P = 0.05, respectively). Adenocarcinoma patients with survival data (n = 587) showed higher fractions of resting mast and resting CD4 T cells, and lower M0 macrophages than squamous cell carcinoma (n = 254), which were associated with OS (HR = 0.95,P = 0.04; HR = 0.97,P = 0.01; HR = 1.03,P = 0.01, respectively). Fractions of memory B cells, naive CD4 T cells and neutrophils had different associations with survival depending on the subtype. Smokers had had higher fractions of regulatory T cell, follicular helper T cell, neutrophil and M2 macrophage, which were associated with shorter survival (HR = 1.3,P <0.01; HR = 1.13,P = 0.02; HR = 1.09,P = 0.03; HR = 1.04,P = 0.02, respectively). Conclusion Pretreatment differences in immune cell composition in NSCLC are associated with survival and depend on smoking status and histological subtype. Smokers' immune composition is associated with lower survival.

KW - adenocarcinoma

KW - biostatistics

KW - immune microenvironment

KW - non-small cell lung cancer

KW - smoking

KW - squamous cell carcinoma

KW - TUMOR-INFILTRATING LYMPHOCYTES

KW - MAST-CELLS

KW - T-CELLS

KW - PROGNOSTIC BIOMARKER

KW - CIGARETTE-SMOKING

KW - EXPRESSION

KW - LANDSCAPE

KW - MACROPHAGES

KW - BLOCKADE

KW - PD-L1

U2 - 10.1002/cti2.1142

DO - 10.1002/cti2.1142

M3 - Article

VL - 9

JO - Clinical & translational immunology

JF - Clinical & translational immunology

SN - 2050-0068

IS - 6

M1 - 1142

ER -

ID: 127848476